We are live on ! Find out more

Nuwellis

NUWE

Market cap $2.3M

5.68 USD

-0.10

1.73%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

5.65

-0.03

0.53%

1 day

-1.73%

5 days

105.8%

1 month

-12.35%

3 months

-85.82%

6 months

-98.4%

Year to date

-99%

1 year

-99.53%

5 years

-100%

10 years

-100%

About: Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Employees: 38

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

ULTRA-Peds Registry evaluated 91 pediatric patients across seven leading children's hospitals, providing important clinical evidence which the Company intends to use to support its proposed label expansion of Aquadex's indication to patients weighing 5 kg and above ULTRA-Peds Registry evaluated 91 pediatric patients across seven leading children's hospitals, providing important clinical evidence which the Company intends to use to support its proposed label expansion of Aquadex's indication to patients weighing 5 kg and above

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company's next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform.

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow® system in providing precise, controlled fluid removal for patients who require individualized fluid management.

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure.

Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution

Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch.

Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

See News Rankings

Price charts implemented using Lightweight Charts™